Vaxcyte, Inc. (5VA.F)

Compare

69.50

-1.00

(-1.42%)

At close: March 3 at 8:08:39 AM GMT+1

Vaxcyte, Inc. (PCVX): Among the Cash-Rich Mid Cap Stocks to Buy Now

We recently compiled a list of the 10 Cash-Rich Mid Cap Stocks To Buy Now. In this article, we are going to take a look at where Vaxcyte, Inc. (NASDAQ:PCVX) stands against the other cash-rich mid cap stocks. Cash flow is the money moving in and out of a business over a set period. It is […]

Insider Monkey 44 minutes ago

PCVX
Why Vaxcyte, Inc. (PCVX) Is One of the Best Vaccine Stocks to Buy According to Hedge Funds

We recently published a list of the 10 Best Vaccine Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Vaxcyte, Inc. (NASDAQ:PCVX) stands against the other best vaccine stocks to buy now. What Will Trump’s Tariffs Mean for the Pharma Industry? On February 24, CNBC […]

Insider Monkey 5 days ago

PCVX
Q4 2024 Vaxcyte Inc Earnings Call

Q4 2024 Vaxcyte Inc Earnings Call

Thomson Reuters StreetEvents 5 days ago

PCVX
Vaxcyte Inc (PCVX) Q4 2024 Earnings Call Highlights: Strong Financial Health and Promising ...

Vaxcyte Inc (PCVX) reports robust cash reserves and significant progress in vaccine programs, despite anticipated expense increases and regulatory challenges.

GuruFocus.com 5 days ago

PCVX
Vaxcyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

-- Completed Successful VAX-31 Phase 2 Adult Program; Company Remains on Track to Initiate VAX-31 Adult Phase 3 Pivotal, Non-Inferiority Study by Mid-2025 and Announce Topline Safety, Tolerability and Immunogenicity Data in 2026 -- -- Company Expects to Announce Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series of VAX-24 Infant Phase 2 Study by the End of First Quarter, Followed by Topline Data from Booster Dose by the End of 2025 -- -- Initiated Second and Fi

GlobeNewswire 6 days ago

PCVX
Vaxcyte, Inc. (PCVX): Among the Stocks That Will Go to The Moon According to Analysts

We recently compiled a list of the 15 Stocks That Will Go to The Moon According to Analysts. In this article, we are going to take a look at where Vaxcyte, Inc. (NASDAQ:PCVX) stands against the other stocks. The Stock Market Under Trump Admin While stocks initially fell based on worries regarding Trump tariffs on America’s […]

Insider Monkey 6 days ago

PCVX
It's Official: The Senate Will Let Robert F. Kennedy Jr. 'Go Wild' On Health Care

The Senate voted Thursday to put RFK Jr. in charge of health. It's unclear how he will impact biotech stocks.

Investor's Business Daily 18 days ago

MNMD

MRNA

CMPS
Vaxcyte to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025

SAN CARLOS, Calif., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that it will report financial results for the fourth quarter and full year 2024 after market close on February 25, 2025. Company management will host a conference call and webcast beginning at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial

GlobeNewswire 19 days ago

PCVX
Why Vaxcyte, Inc. (PCVX) Is Among the Best Healthcare Stocks To Buy According to Analysts

We recently compiled a list of the 12 Best Healthcare Stocks to Buy According to Analysts. In this article, we are going to take a look at where Vaxcyte, Inc. (NASDAQ:PCVX) stands against the other healthcare stocks. McKinsey reported that, since 2019, the US healthcare industry witnessed significant financial pressure. This is evidenced by the fact that […]

Insider Monkey 23 days ago

PCVX
Vaxcyte advances second stage of Phase 2 study evaluating VAX-31

Vaxcyte (PCVX) announced that the first study participants have been dosed in the second and final stage of the ongoing Phase 2 study of VAX-31 in healthy infants. Advancement to Stage 2 follows a blinded assessment of the Stage 1 safety and tolerability data per the study protocol. This study is evaluating the safety, tolerability and immunogenicity of VAX-31, a 31-valent pneumococcal conjugate vaccine candidate designed to prevent invasive pneumococcal disease, in healthy infants. The Company

TipRanks 25 days ago

PCVX
Vaxcyte enters final stage of Phase II pneumococcal vaccine trial in infants

Vaxcyte anticipates sharing topline data from the trial’s primary three-dose immunisation series in mid-2026.

Clinical Trials Arena 25 days ago

PCVX
Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants

-- Advancement to Stage 2 of Infant Study Supported by Review of Stage 1 Safety and Tolerability Data -- -- Company Expects to Announce VAX-31 Infant Study Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series in Mid-2026, Followed by Topline Data from the Booster Dose Approximately Nine Months Later -- -- VAX-31 is Designed to Cover Approximately 94% of Invasive Pneumococcal Disease and Approximately 93% of Acute Otitis Media in U.S. Children Under Five -- -- Com

GlobeNewswire 26 days ago

PCVX
MRK Gets Positive CHMP Nod for 21-Valent Pneumococcal Jab Capvaxive

The Committee for Medicinal Products for Human Use recommends approval for Merck's pneumococcal 21-valent conjugate vaccine, Capvaxive.

Zacks 28 days ago

PFE

SNY

PCVX
Vaxcyte to Present at the Guggenheim SMID Cap Biotech Conference

SAN CARLOS, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that Company management will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference in New York on Thursday, February 6, 2025 at 9:30 a.m. ET / 6:30 a.m. PT. A live webcast of the fireside chat can be accessed through the Investors &

GlobeNewswire last month

PCVX
Why Vaxcyte, Inc. (PCVX) Is One of the Best Russell 2000 Stocks to Invest in According to Analysts?

We recently compiled a list of the 10 Best Russell 2000 Stocks to Invest in According to Analysts. In this article, we are going to take a look at where Vaxcyte, Inc. (NASDAQ:PCVX) stands against other best Russell 2000 stocks to invest in according to analysts. The Russell 2000 Index is a widely followed benchmark that […]

Insider Monkey last month

PCVX

^RUT
Sanofi's 21-Valent Pneumococcal Vaccine Enters Phase III

SNY begins phase III study for its 21-valent pneumococcal conjugate vaccine for treating invasive pneumococcal disease in infants and toddlers.

Zacks 2 months ago

SNY

PCVX

PFE
Is Vaxcyte, Inc. (PCVX) the Best Performing Biotech Stock in 2024?

We recently compiled a list of the 10 Best Performing Biotech Stocks in 2024. In this article, we are going to take a look at where Vaxcyte, Inc. (NASDAQ:PCVX) stands against the other biotech stocks. The Booming Biotechnology Sector The biotechnology sector is expanding quickly due to rising demand for novel therapies, advancement in technology, and […]

Insider Monkey 2 months ago

PCVX
What Makes Vaxcyte (PCVX) An Investment Bet?

TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” third-quarter 2024 investor letter. A copy of the letter can be downloaded here. In the quarter the fund returned 6.50% (gross) and 6.24% (net), compared to an 8.41% return for the Russell 2000 Growth Index. Global markets performed fairly in […]

Insider Monkey 2 months ago

PCVX
Vaxcyte doses first subject in pneumococcal conjugate vaccine trial in infants

The study aims to assess the vaccine's tolerability, immunogenicity, and safety in preventing invasive pneumococcal disease.

Clinical Trials Arena 2 months ago

PCVX
Vaxcyte Initiates Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants

-- Company Expects to Announce VAX-31 Infant Study Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series in Mid-2026, Followed by Topline Data from the Booster Dose Approximately Nine Months Later -- -- VAX-31 is Designed to Cover Approximately 94% of Invasive Pneumococcal Disease and Approximately 93% of Acute Otitis Media in U.S. Children Under Five -- -- VAX-31 Offers Potential to Protect Vulnerable Population by Providing Greater Coverage Against Both Currentl

GlobeNewswire 2 months ago

PCVX

Performance Overview

Return	5VA.F	S&P 500
YTD	-13.66%	-0.54%
1-Year	+2.96%	+13.87%
3-Year	+213.06%	+34.06%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Vaxcyte, Inc. (5VA.F)

Vaxcyte, Inc. (PCVX): Among the Cash-Rich Mid Cap Stocks to Buy Now

Why Vaxcyte, Inc. (PCVX) Is One of the Best Vaccine Stocks to Buy According to Hedge Funds

Q4 2024 Vaxcyte Inc Earnings Call

Vaxcyte Inc (PCVX) Q4 2024 Earnings Call Highlights: Strong Financial Health and Promising ...

Vaxcyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Vaxcyte, Inc. (PCVX): Among the Stocks That Will Go to The Moon According to Analysts

It's Official: The Senate Will Let Robert F. Kennedy Jr. 'Go Wild' On Health Care

Vaxcyte to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025

Why Vaxcyte, Inc. (PCVX) Is Among the Best Healthcare Stocks To Buy According to Analysts

Vaxcyte advances second stage of Phase 2 study evaluating VAX-31

Vaxcyte enters final stage of Phase II pneumococcal vaccine trial in infants

Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants

MRK Gets Positive CHMP Nod for 21-Valent Pneumococcal Jab Capvaxive

Vaxcyte to Present at the Guggenheim SMID Cap Biotech Conference

Why Vaxcyte, Inc. (PCVX) Is One of the Best Russell 2000 Stocks to Invest in According to Analysts?

Sanofi's 21-Valent Pneumococcal Vaccine Enters Phase III

Is Vaxcyte, Inc. (PCVX) the Best Performing Biotech Stock in 2024?

What Makes Vaxcyte (PCVX) An Investment Bet?

Vaxcyte doses first subject in pneumococcal conjugate vaccine trial in infants

Vaxcyte Initiates Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants

Performance Overview